Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
AUTOR(ES)
Ye, Xuan-Yi, Ling, Qing-Zhi, Chen, Shao-Jun
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
22/06/2017
RESUMO
ABSTRACT The discovery of arteannuin (qinghaosu) in the 20th Century was a major advance for medicine. Besides functioning as a malaria therapy, arteannuin is a pharmacological agent in a range of other diseases, but its mechanism of action remains obscure. In this study, the reverse docking server PharmMapper was used to identify potential targets of arteannuin. The results were checked using the chemical-protein interactome servers DRAR-CPI and DDI-CPI, and verified by AutoDock Vina. The results showed that neprilysin (also known as CD10), a common acute lymphoblastic leukaemia antigen, was the top disease-related target of arteannuin. The chemical-protein interactome and docking results agreed with those of PharmMapper, further implicating neprilysin as a potential target. Although experimental verification is required, this study provides guidance for future pharmacological investigations into novel clinical applications for arteannuin.
Documentos Relacionados
- IMP dehydrogenase from Pneumocystis carinii as a potential drug target.
- Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target
- Potent Activity of Indolequinones against Human Pancreatic Cancer: Identification of Thioredoxin Reductase as a Potential Target
- A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information
- Identification of Cyclin D3 as a Direct Target of E2A Using DamID